Condition: Ovarian Carcinosarcoma · Endometrial Carcinosarcoma · Sponsor: ARCAGY/ GINECO GROUP
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of patients relapsed and received diverse CT producing modest benefits, and nearly all patients will die. After first line CT including platinum salt, monotherapy (doxorubicin or paclitaxel) is frequently used for relapsed patients, but the response rate (RR) is \<20%, progression-free survival (PFS) \<4 months, and OS \<1 year. In this unmet need situation, a better knowledge of these aggressive neoplasms is essential to propose new therapeutic options.
This description comes directly from the study's public registry record.
Isabelle RAY-COQUARD, Professor · +33184852020 · apailhe@arcagy.org
Bénédicte VOTAN · +33184852020 · apailhe@arcagy.org
Always discuss trial participation with your own doctor first.
| ICO Paul Papin | Angers, France | Recruiting |
| CHRU Jean Minjoz | Besançon, France | Active Not Recruiting |
| Centre Régional de Lutte contre le cancer - Institut Bergonié | Bordeaux, France | Recruiting |
| CHU de BREST - Hôpital Cavale Blanche | Brest, France | Not Yet Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| CHU de Limoges - Hôpital Dupuytren | Limoges, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Hôpital Privé du Confluent S.A.S. | Nantes, France | Active Not Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03651206